United States: EYLEA® Proposed Biosimilar M710 BPCIA Appeals Dismissed For Lack Of Jurisdiction - Venable LLP
Sunday, 28 April 2024 ()
On April 12, 2024, the Federal Circuit dismissed CAFC Appeal No. 24-1402 and Cross-Appeal No. 24-1405 for lack of jurisdiction following its February 22, 2024 order directing Regeneron and Mylan / Biocon.
|
||||
You Might Like |
||||
